Program
avacincaptad pegol
Also written as “Avacincaptad Pegol”, “Izervay™” and “Zimura”.
Its studies are mostly in Geographic Atrophy · Macular Degeneration · Polypoidal Choroidal Vasculopathy · Stargardt Disease, led by 2 companies.
Drug pageAvacincaptad pegol: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharmaits history only | 101 open or running | phase 4since May 6, 2025 | Jul 1, 2008 | Jun 30, 2027phase 4 · NCT06970665 |
| Hoffmann-La Roche | 10 open or running | phase 1since Apr 29, 2025 | Apr 29, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named avacincaptad pegolINNProposed as its International Nonproprietary Name in WHO's List 113
- Apr 29, 2025First study: phase 1 study in Geographic AtrophyFirst studyNCT06961370 · 27 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Hoffmann-La Roche leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06961370Geographic Atrophy · United States | 1 | Terminated | Feb 3, 2026 | 27 |
How it is read
Names in the registry
- “Avacincaptad Pegol”, 6 entries
- “avacincaptad pegol”, 3 entries
- “Izervay™”, 1 entry
- “Zimura”, 1 entry
Conditions, from the studies’ own filings
- Geographic Atrophy, 5 studies
- Macular Degeneration, 3 studies
- Polypoidal Choroidal Vasculopathy, 2 studies
- Stargardt Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.